ORAGENICS, INC. Share-based Payment Arrangement, Expense
ORAGENICS, INC. (OGEN) reported Share-based Payment Arrangement, Expense of $555.75 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-16
- ORAGENICS, INC. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $57.68K, a 1465.80% increase year-over-year.
- ORAGENICS, INC. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $330.80K, a 17.88% decline year-over-year.
- ORAGENICS, INC. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $58.22K, a 8.50% decline year-over-year.
- ORAGENICS, INC. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $64.29K, a 19.60% decline year-over-year.
- ORAGENICS, INC. share-based payment arrangement, expense for fiscal 2025 was $555.75K, a 7.69% increase from fiscal 2024.
- ORAGENICS, INC. share-based payment arrangement, expense for fiscal 2024 was $516.05K, a 6.19% decline from fiscal 2023.
- ORAGENICS, INC. share-based payment arrangement, expense for fiscal 2023 was $550.08K, a 25.89% decline from fiscal 2022.
- ORAGENICS, INC. share-based payment arrangement, expense for fiscal 2022 was $742.20K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $555.75K 10-K · filed 2026-03-16 | |||||
| 2024-12-31 | $57.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $388.49K derived: sum of 2 quarters · filed 2026-03-16 | $446.71K derived: sum of 3 quarters · filed 2026-03-16 | $516.05K 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $330.80K 10-Q · filed 2024-11-13 | $389.02K derived: sum of 2 quarters · filed 2024-11-13 | $458.37K 10-Q · filed 2024-11-13 | $457.00K derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2024-06-30 | $58.22K 10-Q · filed 2024-08-09 | $127.56K 10-Q · filed 2024-08-09 | $126.19K derived: sum of 3 quarters · filed 2025-03-14 | $529.00K derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2024-03-31 | $64.29K 10-Q · filed 2024-05-15 | $67.97K derived: sum of 2 quarters · filed 2025-03-14 | $470.78K derived: sum of 3 quarters · filed 2025-03-14 | $534.41K derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-12-31 | $3.68K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $406.49K derived: sum of 2 quarters · filed 2025-03-14 | $470.12K derived: sum of 3 quarters · filed 2025-03-14 | $550.08K 10-K · filed 2025-03-14 | $550.08K 10-K · filed 2024-03-29 | |
| 2023-09-30 | $402.81K 10-Q · filed 2024-11-13 | $466.43K derived: sum of 2 quarters · filed 2024-11-13 | $546.40K 10-Q · filed 2024-11-13 | $142.00K 10-Q · filed 2023-11-09 | $919.37K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $63.63K 10-Q · filed 2024-08-09 | $143.59K 10-Q · filed 2024-08-09 | $516.56K derived: sum of 3 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $79.97K 10-Q · filed 2024-05-15 | $452.93K derived: sum of 2 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $372.97K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $742.20K 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $369.24K 10-Q · filed 2023-11-09 | |||||
| 2013-03-31 | $7.62K 10-Q · filed 2013-05-15 | |||||
| 2012-09-30 | $799.39K 10-Q · filed 2012-11-14 | $795.82K derived: sum of 2 quarters · filed 2012-11-14 | $1.06M 10-Q · filed 2012-11-14 | $1.14M derived: sum of 4 quarters · filed 2013-05-15 | ||
| 2012-06-30 | -$3.58K 10-Q · filed 2012-08-10 | $257.83K 10-Q · filed 2012-08-10 | $339.82K derived: sum of 3 quarters · filed 2013-05-15 | $551.96K derived: sum of 4 quarters · filed 2013-05-15 | ||
| 2012-03-31 | $261.40K 10-Q · filed 2013-05-15 | $343.40K derived: sum of 2 quarters · filed 2013-05-15 | $555.53K derived: sum of 3 quarters · filed 2013-05-15 | $1.28M derived: sum of 4 quarters · filed 2013-05-15 | ||
| 2011-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $294.13K derived: sum of 2 quarters · filed 2012-11-14 | $1.02M derived: sum of 3 quarters · filed 2012-11-14 | $1.14M 10-K · filed 2012-04-16 | ||
| 2011-09-30 | $212.13K 10-Q · filed 2012-11-14 | $939.40K derived: sum of 2 quarters · filed 2012-11-14 | $1.06M 10-Q · filed 2012-11-14 | |||
| 2011-06-30 | $727.26K 10-Q · filed 2012-08-10 | $846.19K 10-Q · filed 2012-08-10 | ||||
| 2010-12-31 | $667.22K 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |